Frontline immunotherapy for NSCLC - the tale of the tail

Nat Rev Clin Oncol. 2020 Feb;17(2):73-74. doi: 10.1038/s41571-019-0317-y.

Authors

Anne C Chiang¹, Roy S Herbst²

Affiliations

¹ Department of Internal Medicine, Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA.
² Department of Internal Medicine, Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA. roy.herbst@yale.edu.

PMID: 31907372
DOI: 10.1038/s41571-019-0317-y

No abstract available

Publication types

Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung*
Humans
Immunotherapy
Ipilimumab
Lung Neoplasms*
Nivolumab

Substances

Ipilimumab
Nivolumab